Our first COVID-19 related monoclonal antibodies are now available: ten antibodies specific to SARS-CoV-2 nucleoprotein and three antibodies specific to Spike (RBD).
Special Offer! Evaluate all these new MAbs 0,5mg free of charge*
Please note that these first antibodies are produced as in vivo products. The same antibodies in recombinant or in vitro formats will be ready in November/December. More clones will become available in the coming weeks as well.
Additionally we have limited amounts of R&D samples of clones that are not available as commercial products yet: twelve antibodies specific to SARS-CoV-2 nucleoprotein and two specific to Spike (RBD), please inquire below. For a full list of antibodies and preliminary pair recommendations, see the data sheets.